Oneness has been notified by the consultant company that the Indonesia BPOM has accepted the NDA application of the diabetic foot ulcer new drug, Fespixon. Oneness has been notified by the consultants company that the Indonesia BPOM have accepted the NDA application of FESPIXON, the diabetic foot ulcers new drug. Once disapproved by competent authority or each of clinical trials (include interim analysis) results less than statistically significant sense, the risks and the associated measures the Company may occur:NA.

After obtaining official approval or the results (include interim analysis) of statistically significant sense, the future strategy:NA. Accumulated investment expenditure incurred: No disclosure of investment expenditure at the moment in consideration of future marketing strategies to protect the company and investors interests. Upcoming development plan: Scheduled completion date: The second phase 3 trial in the US is scheduled to complete in 3-4 years after initiation.